Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.41 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612281 | 0.83 | LOXL2 (0.35) | LOXL2CYP3A4TSHR | |
| SCHEMBL16112198 | 0.82 | IDO1 (0.44) | MAOAMAOBKDM1AIDO1AGXT | |
| SCHEMBL30612246 | 0.81 | CHRNA7 (0.40) | CYP3A4 | |
| SCHEMBL5790163 | 0.80 | MAOA (0.38) | MAOAMAOBKDM1ARCOR1IDO1 | |
| SCHEMBL31294910 | 0.77 | MAOA (0.37) | MAOAMAOBKDM1ARCOR1CYP3A4 | |
| SCHEMBL30612254 | 0.76 | — | — | |
| SCHEMBL23500896 | 0.76 | HRH1 (0.39) | MAOAMAOB | |
| SCHEMBL7371048 | 0.76 | CYP3A4 (0.39) | MAOAMAOBKDM1ACYP3A4HSD11B1 | |
| SCHEMBL30311609 | 0.76 | MAOA (0.36) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL30936701 | 0.73 | MEN1 (0.34) | MAOAMAOBKDM1ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119955635-A | Yeast strain for synthesizing 2-methylbenzimidazole compound and application thereof | 茅台学院 | 2025-05-09 | — | — | CN | claimed |
| CN-119955635-A | Yeast strain for synthesizing 2-methylbenzimidazole compound and application thereof | 茅台学院 | 2025-05-09 | — | — | CN | disclosed |
| CN-115710233-A | Modulators of CFTR and methods of use thereof | 加利福尼亚大学董事会 | 2023-02-24 | — | — | CN | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | MAOA 1749/4885MAOB 1294/4885KDM1A 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.